Article Text

Download PDFPDF

Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?
  1. W Doehner,
  2. S D Anker*
  1. Division of Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
  1. Correspondence to:
    Wolfram Doehner
    MD, PhD, Division of Applied Cachexia Research, Department of Cardiology, Charité, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany ; wolfram.doehnercharite.de

Abstract

A substantial body of evidence has accumulated to suggest a role for the xanthine oxidase metabolic pathway in the pathophysiology of chronic heart failure and other cardiovascular diseases

  • BNP, brain natriuretic peptide
  • CHF, chronic heart failure
  • NO, nitric oxide
  • XO, xanthine oxidase
  • allopurinol
  • heart failure
  • xanthine oxidoreductase
View Full Text

Statistics from Altmetric.com

Footnotes

  • * Also Department of Clinical Cardiology, National Heart & Lung Institute, Imperial College, London, UK

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society